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Abstract
Background: Chest radiographs are used for diagnosis and severity assessment in tuberculosis (TB). The extent of
disease as determined by smear grade and cavitation as a binary measure can predict 2-month smear results, but
little has been done to determine whether radiological severity reflects the bacterial burden at diagnosis.
Methods: Pre-treatment chest x-rays from 1837 participants with smear-positive pulmonary TB enrolled into the
REMoxTB trial (Gillespie et al., N Engl J Med 371:1577–87, 2014) were retrospectively reviewed. Two clinicians
blinded to clinical details using the Ralph scoring system performed separate readings. An independent reader
reviewed discrepant results for quality assessment and cavity presence. Cavitation presence was plotted against
time to positivity (TTP) of sputum liquid cultures (MGIT 960). The Wilcoxon rank sum test was performed to
calculate the difference in average TTP for these groups. The average lung field affected was compared to log 10
TTP by linear regression. Baseline markers of disease severity and patient characteristics were added in univariable
regression analysis against radiological severity and a multivariable regression model was created to explore their
relationship.
Results: For 1354 participants, the median TTP was 117 h (4.88 days), being 26 h longer (95% CI 16–30, p < 0.001)
in patients without cavitation compared to those with cavitation. The median percentage of lung-field affected was
18.1% (IQR 11.3–28.8%). For every 10-fold increase in TTP, the area of lung field affected decreased by 11.4%.
Multivariable models showed that serum albumin decreased significantly as the percentage of lung field area
increased in both those with and without cavitation. In addition, BMI and logged TTP had a small but significant
effect in those with cavitation and the number of severe TB symptoms in the non-cavitation group also had a small
effect, whilst other factors found to be significant on univariable analysis lost this effect in the model.
Conclusions: The radiological severity of disease on chest x-ray prior to treatment in smear positive pulmonary TB
patients is weakly associated with the bacterial burden. When compared against other variables at diagnosis, this
effect is lost in those without cavitation. Radiological severity does reflect the overall disease severity in smear
positive pulmonary TB, but we suggest that clinicians should be cautious in over-interpreting the significance
of radiological disease extent at diagnosis.
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Background
Since their introduction in routine clinical practice in
the 1920s, chest radiographs have been used as a pri-
mary tool to diagnose and manage pulmonary tubercu-
losis (PTB) [1–3]. To date, despite their limitations and
the availability of computed tomography, they remain
the most commonly used tool in PTB diagnosis and
management worldwide [4–6]. The chest x-ray (CXR)
has been used not only as a diagnostic tool, but also to
estimate disease severity in multiple TB studies and clin-
ical trials [7–9].
There are several methods of grading the radiological
severity of disease by estimating the extent of lung field
that is ‘abnormal’, including the WHO grading system
[10] or the US National Tuberculosis and Respiratory
Disease Association classification [11]. In 2010, Ralph et
al. [12] created a simple validated scoring system (using
a score out of 140) from findings that the proportion of
lung fields affected by disease at diagnosis of PTB was
associated with a greater acid fast bacilli (AFB) smear
grade and that the presence of cavitation (but not num-
ber or size of cavitation), along with the percentage of
lung field affected on CXR, predicted 2-month smear
positivity on treatment. This has gained some currency
in studies describing radiological severity [13–15] and in
a subsequent study that validated this approach [16].
The relationship between radiological appearance and
disease severity has been assessed by comparison with
measures of bacterial load such as smear microscopy
and culture [17–21]. At diagnosis, the presence of cavi-
tation visible on CXR has been associated with a higher
sputum AFB smear grade [12, 17, 22]. The time taken
for specimens in automated liquid culture to signal posi-
tive is inversely related to bacterial load [13, 23, 24].
Using this concept, a study of 95 images showed that
the presence of cavitation on CXR was associated with a
shorter time to positivity (TTP) [21]. More recently,
some studies have shown that patients with cavitation
have a higher bacterial load as judged by TTP in liquid
culture [23, 24]. Another study of 244 patients with
radiographic assessment of cavitation found that the col-
ony forming units per milliliter were significantly higher
in those with cavitation; this was also true using TTP as
a marker for bacterial load [22].
In his seminal review of post mortem examinations of
patients with TB, Canetti [25] described a difference in
the number of bacteria in lung tissue of samples with
cavities compared to those with caseous necrotic tissue
only and areas of alveolitis. He found that tubercle bacilli
were abundant in the inner layer of a cavity, abundant
but less so in a solid area of caseous tissue, and rare
within areas of inflammatory tissue. As Canetti de-
scribed bacilli-rich areas as well as areas of inflammatory
change, one would think that the host’s inflammatory
response in addition to the bacterial load should affect
the findings on the CXR prior to treatment. We look at
a number of patient factors that may affect this host re-
sponse and which have been associated with radiological
findings in other studies, such as on HIV status [26], dia-
betes mellitus status [27, 28], age [29], ethnicity [30, 31],
and gender [32], to investigate what host factors affect
radiological severity. Hypoalbuminemia at diagnosis of
PTB and low body mass index (BMI) are surrogates of
disease severity known to lower survival rates [33, 34].
TB symptoms at diagnosis have been associated with
worse burden of disease [35].
With so much weight put on the extent of radiological
findings, little is known about what this reflects. We use
the REMoxTB database [36] of patients from Africa and
Asia with PTB to determine whether radiological extent
of disease judged by the CXR severity score correlates
with M. tuberculosis bacterial load as measured by
Mycobacteria-Growth-Indicator-Tube (MGIT) TTP.
Methods
Study sites and patients
Data were collected from the REMoxTB clinical trial,
which compared the use of two 4-month moxifloxacin-
containing regimens to the standard 6 month first line
treatment for PTB [36]. Between 2007 and 2012, 1931
patients were enrolled from 51 sites across 8 countries
in Africa and Asia and the protocol mandated pre-
treatment postero-anterior CXRs, sputum sampling for
AFB smear and culture, and routine blood tests (includ-
ing liver function tests, albumin levels and HIV testing).
During the trial, study patients were excluded if they
had severe medical comorbidities or were already taking
antiretroviral treatment for HIV prior to study enroll-
ment. In this study, all patients were adults aged 18 years
or more, who had smear- and culture-positive PTB by
molecular speciation.
CXR scoring
The CXR images were taken at the clinical sites by a
radiographer and either uploaded as a digital image
(DICOM file) or presented to the clinical site staff as a
plain film. Plain films were digitalized with digital pho-
tography using a standard protocol to ensure images
were of an adequate quality. An early assessment of
‘readability’ was performed and, where films were judged
poor, sites were asked to re-take the images. All images
were converted into DICOM files for evaluation.
The digital images were read independently by two
clinicians (SHG and SEM) using the Osirix medical
imaging software on Apple iMAC computers with at
least 1920 × 1080 pixel screens, and readers were en-
couraged to take regular breaks during the reading
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process. Images were sent to readers by study site and
were read in the same order.
Both readers followed standardized criteria to establish
whether an image was of sufficient quality for analysis
(Table 1). If deemed satisfactory, the image was assessed
for the presence of cavitation and a measure of percent-
age of abnormal lung field. In the case of discrepant re-
sults on readability or presence of cavitation, a third
reader blinded to the primary assessment reviewed the
film (FC). Only those images that the first two readers
agreed on for readability or those that the third reader
deemed readable were used in the final analysis. The
final result for cavity presence was based on agreement
between the primary readers or, if discrepant, the majority
result including the third reading. The percentage of lung
field affected was calculated using the method described
by Ralph et al. [12], where the reader divides the lung
fields into quadrants and by observation scores each quad-
rant by its percentage of abnormal opacification. The
scores are then added together and divided by four to pro-
duce a total percentage of lung field affected by disease.
Microbiological and clinical data
Sputum samples and demographic data were collected
as part of the clinical trial protocol at screening and
baseline visits, prior to starting treatment. Sputum sam-
ples were either early morning samples or spot samples,
none of which were induced. The samples were proc-
essed by standard methodology and graded as described
in the trial report. Samples that were re-treated due to
contamination were not included in the analysis as this
process altered the calculated TTP and, thus, could not
guarantee an accurate quantification result. As part of
the pre-treatment assessment, participants were tested
for HIV and were asked about a history of diabetes mel-
litus. In addition, a series of questions about symptoms
were asked and symptoms graded by severity using the
modified Division of AIDS system [37] (Table 2).
Statistical analysis
The inter-reader variability was presented on a Bland–
Altman plot using the final severity scores from readers
1 and 2. The average of the two readers’ calculation of
the percentage of lung field affected was used with the
final results of cavity assessment. Images where readers
disagreed by 1.96 standard deviations or more were not
included in the analysis to ensure accuracy in the aver-
age percentage value. The presence or absence of cavita-
tion was plotted against TTP and a Wilcoxon rank sum
test to calculate the difference in average TTP for each of
the two groups was performed. The average percentage
area of lung field affected was compared to log10TTP using
linear regression and plotted on a scatterplot.
Baseline clinical and biochemical findings (age, sex,
ethnicity, BMI, serum albumin, number of grade 3 or
4 TB symptoms, HIV status and type II diabetes status)
and radiological severity score were included in a uni-
variable regression analysis. Those found to be signifi-
cant (p < 0.05) were used to create a multivariable
regression model to determine the relationship of these
characteristics with the radiological severity score. For
this process the participants were put into two groups;
those with cavitation and those without. Wilcoxon rank
sum tests and χ2 tests were used to compare both
groups. All statistical analysis was performed using R
statistical software [38].
Ethical approval
This study was performed within the scope of the
approvals provided for the REMoxTB clinical trial [36].
Results
Out of 1931 patients randomized for the trial, 1837 had
CXRs taken within the required protocol time frame.
Following the three-reader quality assessment, 1713 im-
ages were deemed readable. Taking into account avail-
able data required for analysis, including non-retreated
culture results with TTP data, the total number of cases
was 1354 from 47 study sites (Fig. 1). The baseline char-
acteristics and findings for the 1354 cases with available
matching data are shown in Table 3 and breakdown of
participants by site in Table 4. A comparison of the
characteristics between the included and excluded co-
hort are also shown to ensure sampling bias was not an
issue (Table 5).
Reader agreement
There was agreement for 1394 (76%) of the 1837 images
available for either their readable quality or the presence
or absence of cavitation. Agreement between the two
readers on cavitation presence was 0.495 by Cohen’s
Kappa score (95% CI 0.45–0.54, p < 0.001), where a value
of < 0.4 is poor, 0.4–0.75 is fair to good, and > 0.75 to 1
is excellent [39]. The level of agreement when assessing
the percentage of the area of lung field affected was
illustrated using a Bland–Altman plot (Fig. 2).
Table 1 Inclusion and exclusion criteria for deeming an image
of sufficient quality for reading
Inclusion Exclusion
Postero-anterior film Artefacts obscuring the view of
the lung fields
A full view of lung fields – the
whole thorax with the first rib,
lateral ribs and costophrenic
angles in view
Images acquired more than
4 weeks prior to pretreatment
visit or more than 3 weeks
after this
Adequate penetration of film to
allow ribs and lung parenchyma
to be distinguished
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Cavity presence and bacterial load
The number of images confirmed to have cavitation
visible was 1049 (77.5%) of 1354. The median TTP
for MGIT samples from all 1354 patients was 117 h
(4.88 days) with an interquartile range of 89 h (3.7 days)
to 153 h (6.4 days). Figure 3 shows a boxplot of distribu-
tion of TTP between those without and with cavitation on
CXR at baseline. This demonstrates that the median TTP
is 26 h greater in those patients without compared to
those with cavitation (95% CI 16–30, p < 0.001, Wilcoxon
rank sum test).
Extent of radiological disease and bacterial load
The median percentage of lung fields affected on the chest
radiographs was 18.1% (interquartile range 11.3–27.5%).
Figure 4 shows a scatterplot of the percentage of lung field
affected against the sputum culture log10TTP values for
the 1354 patients. Using linear regression for every 10-fold
increase in TTP, the area affected decreases by 11.4%
(p < 0.001, 95% CI 14.9–7.9%).
Multivariable regression model: pre-treatment factors and
baseline radiological severity
The percentage of lung fields affected was compared to
other parameters in two groups; those with cavity pres-
ence and those without cavitation. Characteristics of
these two groups are shown in Table 6, with both groups
showing statistical differences in albumin levels (lower
albumin levels in the cavity group), ethnicity (African
participants having a higher level of cavitation and
Asians with a greater number without cavitation), TTP
(lower TTP in the cavity group), and percentage of lung
field affected (greater in the cavity group). HIV status,
diabetes status, culture TTP (log10TTP), serum albumin,
number of grade 3 or 4 TB symptoms, BMI, age, and
ethnicity were found to have a statistically significant
Table 2 Division of AIDS (DAIDS) grading of adverse event (AE) severity (modified version). This describes the grading system
referred to in this study to describe the severity of TB symptoms such as cough, night sweats, weight loss, and hemoptysis
Parameter Grade 1 Grade 2 Grade 3 Grade 4
Clinical AE NOT identified
elsewhere in this DAIDS
AE grading table























NA 5–9% loss in body weight
from baseline
10–19% loss in body
weight from baseline
≥ 20% loss in body





Fig. 1 Flow diagram showing breakdown of final cohort for analysis
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effect on the radiological severity of chest images by uni-
variable analysis in the group with cavity disease
(Table 7). In the non-cavitatory disease group, only eth-
nicity, serum albumin, and number of grade 3 symptoms
were statistically significant on univariable analysis. Put-
ting these significant variables in a multivariable regres-
sion model (Table 8) in those patients with cavitatory
disease, the factors found to have a significant effect on
the area of lung field affected were BMI, serum albumin,
and log10TTP. In those without cavitatory disease, the
factors found to have a significant effect on area of lung
field affected were the number of grade 3 and 4 symp-
toms and serum albumin.
Discussion and conclusions
The REMoxTB study provided a unique opportunity to
address important questions about the role of radiology
in the diagnosis and evaluation of severity of TB infec-
tion in a large group of smear- and culture-positive
patients with PTB that spanned two continents. The
subjectivity of CXR interpretation has been a longstand-
ing concern in clinical practice and there have been mul-
tiple attempts to develop methods to standardize image
reading in order to reduce reader variability [12, 40–42].
This study shows that agreement between readers in
cavity assessment was moderate (Kappa score 0.495),
comparable to other studies that found a Kappa agreement
variation on cavity presence from 0.24 to 0.7 [43–48]. The
clustering of scores across the x-axis and ‘0’ line of full
agreement on the Bland–Altman plot (Fig. 2) confirms that
the assessment of area of lung field affected is reproducible.
A high proportion of patients in this study had radio-
logical evidence of cavitation (78%), compared with 72%
in a study of 800 Turkish patients [20], 53.1% in a study of
893 USA-based patients [48], and 51% in a recent multi-
center trial of 1692 patients in African sites [49]. Previous
reports have suggested that the presence and number of
cavities is related to bacterial load [12, 19–22, 50], but
most of these studies were small, with an average of 138
patients (a range of 61–244). Using this large sample of
patients we were able to show that there is a statistically
significant reduction in the TTP (our surrogate for bacter-
ial load) in patients with cavities compared to those with-
out, with a median reduction of 26 h (p < 0.001). The large
number of patients in this study provides the statistical
power to demonstrate this unequivocally. It would, how-
ever, be reasonable to assume that such a reduction in
TTP is of modest clinical significance, given that the repli-
cation rate of M. tuberculosis is approximately 14–24 h.
Table 3 Baseline characteristics of final 1354 subjects
Baseline characteristic N (%) Median IQR (1st,
3rd quartile)













Albumin (g/L) 34 30, 38
Body mass index (kg/m2) 18.5 16.9, 20.3










Average area affected (%) 18.13 11.25, 27.5
Table 4 The 47 sites across 8 countries where the participants
(1354) were recruited
COUNTRY SITE N (total 1354)













Thailand (2 sites) Bangkok 104
Malaysia Kuala Lumpur 56
China Tianjin 18
India (29 sites) Dehli, Agra, Jaipur 252
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Looking at the two groups of cavity and no cavity, the
cavity group had lower albumin, TTP, and greater area
affected suggesting that those with cavities appear to
have other markers of ‘severe’ disease.
More cavities were proportionately found in the
African cohort than in the Asian cohort. This raises the
question of whether ethnicity plays a role in cavity
Table 5 A comparison of the included and excluded cohorts. Using χ2 tests and Wilcoxon rank sum test p values are provided
Included (n = 1354) Excluded (n = 359)
Baseline characteristic N (%) Median IQR (1st, 3rd quartile) N (%) Median IQR (1st, 3rd quartile) p value
Age (years) 31.6 24.1, 41.9 29.8 24.2, 40.8 0.39
Body mass index (kg/m2) 18.5 16.9, 20.3 18.2 16.3, 20.3 0.06
Sex 0.32
Male 959(70.8%) 244 (68%)
Female 395 (29.2%) 115 (32%)
Ethnicity 1.0
African 924 (68.2%) 245 (68.2%)
Asian 430 (31.8%) 114 (31.8%)
Diabetes 0.30
Yes 69 (5%) 13 (3.6%)
No 1285 (95%) 346 (96.4%)
HIV 0.10
Yes 104 (7.7%) 18 (5%)
No 1250 (92.3%) 341 (95%)
Albumin (g/L) 34 30, 38 35 30, 39.3 0.19
Time to positivity (hours) 117 89, 153 (n = 79 with values) 105 85.5, 140.5 0.10
Cavity 1.0
Yes 1049 (77.5%) 278 (77.4%)
No 305 (22.5%) 81 (22.6%)
Average area affected 18.13 11.3, 27.5 21.88 11.9, 32.5 0.001
Fig. 2 Bland–Altman plot demonstrating the level of agreement
between readers 1 and 2 in scoring the 1713 images for radiological
severity (x axis: the mean average numerical score between readers
1 and 2, y axis: the difference in scores for each image between
readers 1 and 2). Horizontal lines show the mean ± 1.96 standard
deviations; 3.34 (23.11−16.44) (SD = 10.10)
Fig. 3 Boxplot of TTP distribution comparing subjects without and
those with cavitation present on CXR. Thick black horizontal lines
represent the median values with the interquartile range being the
horizontal edges of the boxes. The overall range lies out with these
and extreme outliers above the plots
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formation and the immune response to TB addressed in
previous studies [29–31]. A recent study suggests that
the pattern of radiological presentation at diagnosis is
associated with certain inflammatory profiles in patients
[30]. Significant differences between the cytokine
response of Africans and Eurasian patients rather than
Mycobacterial strain type have been demonstrated [30, 31].
This may be a contributing factor to the radiological sever-
ity of patients at presentation as we also noted a small but
significant difference through univariate analysis of radio-
logical score between patients of African origin and those
of south and southeast Asian origin that was lost when put
into a multivariable analysis.
The study also shows a relationship between overall
area of lung field affected on radiograph and bacterial
load with a very shallow association seen on the scatter-
plot presented (Fig. 4). The association described that it
would require a 10-fold increase in TTP to change the
area affected by 11%, suggesting that patients with a
higher bacterial load do have greater radiological severity
but the effect of this association is small.
Our study addresses the effect of variables such as
ethnicity, initial bacterial load, nutritional status, HIV
status, sex, age, symptom severity, and diabetic status by
multivariable-regression analysis on radiological severity.
When weighted against each other in a model, bacterial
load does not have a statistically significant effect on the
degree of diseased lung field on CXR in the group with
non-cavitatory disease and, again, a modest effect in
those with cavitation. This fits with the autopsy findings
that Canetti described, where higher bacillary burden
was found within cavities and their surrounding tissues
but was much lower within the inflammatory, non-
cavitating tissue alone [25].
The only variable found to be related to the severity of
the CXR at diagnosis is the serum albumin level in both
the cavity and non-cavity groups. Poor nutritional status of
patients with TB, using pre-treatment albumin levels and
BMI as surrogate markers of nutritional status [33, 34, 51],
has been associated with poorer treatment outcomes and
death. In our study, patients with low serum albumin con-
centration at diagnosis (at a level of 15 g/L at the lowest)
had a contributing effect to the radiological severity, but
again to a modest degree, with a 0.65% and 0.48% de-
crease in area affected for every 1 g/L increase in serum
albumin at baseline in the cavitatory and non-cavitatory
groups, respectively (Fig. 5).
Through this analysis, our findings show that the fac-
tors affecting the appearance of the radiograph are likely
to be multifactorial and to include host parameters such
as ethnicity, age, co-morbidities, the bacterial load, and
degree of disease progression. The interaction of the fac-
tors affecting the inflammatory response of an individual
to PTB infection is being explored in other research.
We included those with HIV and type II diabetes melli-
tus in our cohort and found no significant effect on the
radiological severity. This may be due to our HIV cohort
being a select group with CD4 counts > 250 at PTB diag-
nosis without preceding anti-retrovirals and those with
diabetes with less severe disease as a requirement for the
clinical trial. They may, therefore, not reflect the full
spectrum of morbidity and its effects on CXR severity.
In summary, our study is the largest review of radi-
ology in a well characterized patient group with smear-
and culture-positive PTB and suggests that, although
CXR is a valuable tool for diagnosis, its use for judging
the bacterial burden of disease has limited value. This is
not unexpected, as the radiological image appears to be
a composite of the interaction of disease pathology
caused by the organism, the severity of the immune re-
sponse and the nutritional status of the patient. The
statistical power of this large study has enabled us to
Fig. 4 Scatterplot showing the log10TTP (hours) from baseline
sputum cultures against the percentage of lung field affected on
the CXRs
Fig. 5 Scatterplot of the serum albumin levels (x-axis) and the
percentage of lung field affected on the CXR (y-axis) for all 1354
participants. A linear regression line shows a steady decrease in
serum albumin as more area is affected by disease
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precisely measure the associations between CXR severity
and other factors measured. The effect of serum albumin
level on the radiological severity serves as an indicator
that hypo-albuminemia is a marker of disease severity,
as shown in other studies where it has been indicated to
predict poor outcome in PTB [52]. The full value of
CXR as a prognostic marker is yet to be seen and
warrants further analysis. Although the associations
between CXR severity and other factors conform with
our expectations that patients with higher bacterial
burden have more extensive disease, the small size of
the effect and the finding that, in a multivariable
Table 6 Characteristics of those with and without cavitation used in the analysis comparing other baseline factors and radiological
severity on CXR at diagnosis
WITH CAVITY (n = 1049) WITHOUT CAVITY (n = 305) p value
Baseline characteristic n Median IQR (1st, 3rd quartile) n Median IQR
Age (years) 31.4 23.7, 41.0 32.1 25.2, 44.2 0.03
Sex 0.95
Male 742 (70.7%) 217 (71.1%)
Female 307 (29.3%) 88 (28.9%)
Ethnicity
African 742 (70.7%) 182 (59.7%) < 0.01
Asian 307 (29.3%) 123 (40.3%)
Diabetes
Yes 50 (4.5%) 19 (6.2%) 0.38
No 1049 (95.5%) 286 (93.8%)
HIV 0.79
Yes 81 (7%) 25 (8.2%)
No 1081 (93%) 280 (91.8%)
No. of Grade 3 + symptoms 68 16 0.51
Albumin (g/L) 33.5 9.0,37.8 37 32.0, 40.0 < 0.01
Body mass index (kg/m2) 18.3 16.9,20.1 19.0 17.3, 21.1 < 0.01
Time to positivity (hours) 112 86.0, 144.0 138 100, 188 < 0.01
Average area affected 20 13.75, 30 10 6.25, 16.9 < 0.01
Table 7 Results of univariable analysis. The β-coefficient represents the change in percentage area of lung field affected for every 1
unit increase in variable. For Log10TTP, this is the change in percentage area affected for every 10-fold increase in TTP
With cavity Without cavity
β-coefficient 95% CI p value B-coefficient 95% CI p value
Age 0.09 (0.03, 0.15) 0.003 −0.0004 (−0.07, 0.07) 0.90
Sex
Male vs. female 0.91 (−0.71, 2.5) 0.27 −0.41 (−2.49, 1.68) 0.70
Ethnicity
Asia vs. Africa −2.33 (−3.95, − 0.73) 0.004 − 2.5 (−4.41, − 0.59) 0.01
Diabetes 1.17 (−2.27, 4.63) 0.05 1.86 (−2.04, 5.77) 0.39
Positive vs. negative
HIV 0.14
Positive vs. negative 2.11 (−0.67, 4.89) 0.01 −2.78 (−6.21, 0.65) 0.11
Albumin (g/L) −0.72 (− 0.82, − 0.61) < 0.001 −0.53 (− 0.68, − 0.38) < 0.001
Body mass index − 0.55 (− 0.76, − 0.33) < 0.001 −0.13 (− 0.41, 0.19) 0.40
MGIT Log10ttp (hours) −8.87 (−13.08, − 4.67) < 0.001 − 2.41 (−7.10, 2.29) 0.31
Grade 3+ tuberculosis symptoms 2.17 (0.33, 4.02) 0.02 5.03 (1.88, 8.17) 0.002
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model, it is outweighed by other patient factors in
those without cavitation and is modest in those with
cavitation would suggest that clinicians should be
cautious in over-interpreting cause of radiological dis-
ease extent at diagnosis.
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Additional file 1: List of ethics committee approving the REMoxTB
study. (DOCX 894 kb)
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Grade 3 + Symptoms 0.05 (−1.68, 1.79) 0.95 3.13 (0.11, 6.15) 0.04
Body mass index −0.50 (−0.72, − 0.27) < 0.001 −0.07 (− 0.33, 0.19) 0.63
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Positive vs. Negative 3.03 (−0.33, 6.40) 0.07
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